Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFOCAL-2: Autoregulation-based Precision Blood Pressure Management in Critical Illness
NCT07296029Phase 2Completed
- Sponsor
- Queen's University
- Start
- Jul 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of norepinephrine, labetalol in critical illness, respiratory failure, Shock, sponsored by Queen's University. Started Jul 2022; status: completed.
02
Drugs
norepinephrinelabetalol
03
Conditions
critical illnessrespiratory failureShock
Beyond the preview
Go deeper on NCT07296029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07296029.